Učitavanje...

Risk of recurrence and bleeding in patients with cancer‐associated venous thromboembolism treated with rivaroxaban: A nationwide cohort study

BACKGROUND: Rivaroxaban could be an attractive alternative to low molecular weight heparin for the treatment of cancer‐associated venous thromboembolism (VTE) but the safety and effectiveness remain unclear. We examined risk of recurrent VTE and major bleeding associated with rivaroxaban treatment o...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Cancer Med
Glavni autori: Søgaard, Mette, Nielsen, Peter Brønnum, Skjøth, Flemming, Kjældgaard, Jette Nordstrøm, Larsen, Torben Bjerregaard
Format: Artigo
Jezik:Inglês
Izdano: John Wiley and Sons Inc. 2019
Teme:
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6434207/
https://ncbi.nlm.nih.gov/pubmed/30767432
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cam4.1997
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!